These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1067 related articles for article (PubMed ID: 28212992)

  • 1. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
    Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Sata M; Sasaki S; Oikado K; Saito Y; Tominaga J; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1506-1513. PubMed ID: 33125784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute interstitial lung disease after nivolumab in three non-small cell lung cancer patients with imaging findings of airway obstruction adjacent to lung tumors.
    Nakahama K; Tamiya A; Taniguchi Y; Sasaki Y; Akira M; Atagi S
    J Infect Chemother; 2017 Dec; 23(12):826-829. PubMed ID: 28818548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
    Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia.
    Fujimoto D; Morimoto T; Ito J; Sato Y; Ito M; Teraoka S; Otsuka K; Nagata K; Nakagawa A; Tomii K
    Lung Cancer; 2017 Sep; 111():1-5. PubMed ID: 28838377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
    Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
    J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study.
    Osawa M; Kudoh S; Sakai F; Endo M; Hamaguchi T; Ogino Y; Yoneoka M; Sakaguchi M; Nishimoto H; Gemma A
    Int J Clin Oncol; 2015 Dec; 20(6):1063-71. PubMed ID: 25967287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Masuda T; Hirano C; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):131-139. PubMed ID: 29143072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of Radiation Pneumonitis History Before Nivolumab with Onset of Interstitial Lung Disease and Progression-free Survival of Patients with Pre-treated Advanced Non-small Cell Lung Cancer.
    Tamiya A; Tamiya M; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Inoue T; Okishio K; Nishino K; Kumagai T; Suzuki H; Hirashima T; Imamura F; Atagi S
    Anticancer Res; 2017 Sep; 37(9):5199-5205. PubMed ID: 28870955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis.
    Sakata S; Matsuoka Y; Kawahara K; Kakiuchi Y; Takaki A; Hirosue A; Yoshida R; Saeki S; Fujii K; Nakayama H
    Respir Investig; 2018 Mar; 56(2):195-198. PubMed ID: 29548660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.
    Kanai O; Kim YH; Demura Y; Kanai M; Ito T; Fujita K; Yoshida H; Akai M; Mio T; Hirai T
    Thorac Cancer; 2018 Jul; 9(7):847-855. PubMed ID: 29782069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
    Hida T; Nishio M; Nogami N; Ohe Y; Nokihara H; Sakai H; Satouchi M; Nakagawa K; Takenoyama M; Isobe H; Fujita S; Tanaka H; Minato K; Takahashi T; Maemondo M; Takeda K; Saka H; Goto K; Atagi S; Hirashima T; Sumiyoshi N; Tamura T
    Cancer Sci; 2017 May; 108(5):1000-1006. PubMed ID: 28266091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance.
    Yamamoto N; Nakanishi Y; Gemma A; Nakagawa K; Sakamoto T; Akamatsu A; Ohe Y
    Cancer Sci; 2021 Nov; 112(11):4692-4701. PubMed ID: 34431585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
    Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
    Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.